Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 11/20 | 0.51 |
| ▸ | CALML3 | P27482 | 4/20 | 0.51 |
| ▸ | MAOB | P27338 | 4/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6647521 | 0.91 | CALML3 (0.47) | MAOACALML3MAOBCYP2C19CYP2C9 | |
| SCHEMBL6798385 | 0.91 | CALML3 (0.49) | MAOACALML3MAOBCYP2C19CYP2C9 | |
| SCHEMBL6671547 | 0.91 | CALML3 (0.52) | MAOACALML3MAOBCYP2C19CYP2C9 | |
| SCHEMBL6795457 | 0.91 | MAOA (0.53) | MAOACALML3MAOBCYP2C19CYP2C9 | |
| SCHEMBL6665107 | 0.90 | CALML3 (0.49) | MAOACALML3MAOBCYP2C19CYP2C9 | |
| SCHEMBL6674271 | 0.90 | CALML3 (0.49) | MAOACALML3MAOBCYP2C19CYP2C9 | |
| SCHEMBL6804500 | 0.90 | CALML3 (0.47) | MAOACALML3MAOBCYP2C19CYP2C9 | |
| SCHEMBL6797896 | 0.90 | CALML3 (0.47) | MAOACALML3MAOBCYP2C19CYP2C9 | |
| SCHEMBL6797548 | 0.90 | CALML3 (0.47) | MAOACALML3MAOBCYP2C19CYP2C9 | |
| SCHEMBL6797036 | 0.90 | CALML3 (0.49) | MAOACALML3MAOBCYP2C19CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1289984-A4 | NOVEL OXAZOLIDINONE DERIVATIVES AND A PROCESS FOR THE PREPARATION THEREOF | DONG A PHARM CO LTD (KR) | 2004-11-24 | — | — | EP | disclosed |
| US-6689779-B2 | PYRIDINE OR PYRIMIDINE SUBSTITUTED; ANTIBACTERIAL ACTIVITY; LOW TOXICITY | DONG A PHARM. CO., LTD. (KR) | 2004-02-10 | — | — | US | disclosed |
| US-20030166620-A1 | Novel oxazolidinone derivatives and a process for the preparation thereof | DONG A PHARM. CO., LTD. (KR) | 2003-09-04 | — | — | US | disclosed |
| EP-1289984-A1 | NOVEL OXAZOLIDINONE DERIVATIVES AND A PROCESS FOR THE PREPARATION THEREOF | Dong A Pharmaceutical Co. Ltd. (KR) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001094342-A1 | NOVEL OXAZOLIDINONE DERIVATIVES AND A PROCESS FOR THE PREPARATION THEREOF | DONG A PHARM. CO., LTD. (KR) | 2001-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166620-A1 | Novel oxazolidinone derivatives and a process for the preparation thereof | OXA1L, ODC1, PDCD4 | MAOA 763/4885CALML3 4610/4885MAOB 593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.